Aortic dissection (AD).


May 4, 2010 - Currently, using conventional imaging modalities to distinguish between acute and chronic aortic dissection (AD) for surgical risk evaluation is not possible. However, in a recent study, researchers were able to use fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) to detect reparatory hypermetabolism in the lacerated aortic wall of acute AD. This allowed them to determine if patients had acute or chronic stable AD.

Investigators at the Clinic for Vascular Surgery in Munich, Germany, analyzed the 18F-FDG uptake in the aortic wall of acute and chronic stable AD in 18 patients. Researchers analyzed the images qualitatively and looked at 18F-FDG uptake patterns and the standardized uptake values (SUVs) of the aortic wall, dissection membrane, and luminal 18F-FDG activity. The standard uptake value (SUV) ratio (maximum SUV in the aorta divided by mean SUV in the blood pool) was calculated to relativize individual luminal 18F-FDG spillover effects.

In contrast to chronic stable AD, all acute or acute progressive AD showed accentuated 18F-FDG uptake at the injured aortic wall or dissection membrane. The maximum SUV of the dissection membrane or aortic wall was significantly higher in acute AD than in chronic stable AD. Thereby, SUV varied from 3.03 to 4.64 (average maximum SUV, 3.84 ± 0.51) for the dissection membrane and from 2.22 to 4.60 (average maximum SUV, 2.94 ± 0.81) for the aortic wall, with false-negative and false-positive outliers. The discrimination between acute and stable AD was improved significantly, and false-positive or negative outliers were eliminated, using the SUV ratio method.

The results indicated 18F-FDG PET/CT might be useful in differentiating acute from chronic AD in clinically unclear cases. Researchers cautioned that larger studies are needed to confirm our preliminary results.

Reference: Reeps, C., Pelisek, J., Bundschuh, R., et al. "Imaging of Acute and Chronic Aortic Dissection by 18F-FDG PET/CT." The Journal of Nuclear Medicine. May, 1 2010; Vol. 51, No. 5

For more information: jnm.snmjournals.org


Related Content

News | Radiopharmaceuticals and Tracers

Nov. 11, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining ...

Time November 12, 2025
arrow
News | FDA

Oct. 30, 2025 — Sirona Medical has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Sirona ...

Time October 30, 2025
arrow
News | Prostate Cancer

Aug. 13, 2025 — A new study from Denmark shows for the first time that men with biochemically recurrent prostate cancer ...

Time August 15, 2025
arrow
News | Mammography

Aug. 5, 2025 — New Lantern has announced the launch of two specialized viewer modes: the Mammography Viewer Mode and PET ...

Time August 05, 2025
arrow
News | Nuclear Imaging

May 5, 2025 — GE HealthCare recently announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance ...

Time May 06, 2025
arrow
News | Prostate Cancer

July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 30, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 25, 2024 — NorthStar Medical Radioisotopes, LLC and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc ...

Time July 25, 2024
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | ASTRO

June 21, 2024 — The American Society for Radiation Oncology (ASTRO) announced today that following a nationwide search ...

Time June 21, 2024
arrow
Subscribe Now